The SURMOUNT-OSA study demonstrates that tirzepatide significantly reduces the severity of obstructive sleep apnea, offering an alternative to mechanical treatments. Obstructive sleep apnea (OSA) affects approximately 30 to 40% of obese individuals. This condition, characterized by repeated interruptions of breathing during sleep, increases cardiovascular risk and significantly deteriorates … Read more
With tirzepatide, weight loss isn’t just fat. Understanding body composition is essential to optimize your treatment. One of the major concerns during rapid weight loss is the loss of muscle mass. With GLP-1 agonists like tirzepatide, this issue is even more relevant as weight loss … Read more
How much weight can one truly lose with Mounjaro? A synthesis of all clinical data available in 2026. The most frequent question from patients considering Mounjaro treatment is simple: how much will I lose? The answer, based on data from 8 major clinical trials involving over 20,000 … Read more
The SURPASS-CVOT study is the largest cardiovascular trial ever conducted with tirzepatide. Its results could transform treatment recommendations. The question of cardiovascular safety for anti-obesity treatments is fundamental. The SURPASS-CVOT (Cardiovascular Outcomes Trial) study was designed to evaluate whether tirzepatide (Mounjaro) reduces the risk of major cardiovascular events in patients … Read more
The SURMOUNT-3 and SURMOUNT-4 studies answer the crucial question: what happens long-term with tirzepatide? One of the main challenges of anti-obesity treatments is long-term weight loss maintenance. The SURMOUNT-3 and SURMOUNT-4 studies, published in 2023 and 2024, provide essential data on the durability … Read more
The SURMOUNT-2 study demonstrates that tirzepatide is equally effective in patients combining type 2 diabetes and obesity, with major glycemic benefits. Following the spectacular results of SURMOUNT-1 in non-diabetic patients, the question arose: would tirzepatide be as effective in patients simultaneously presenting with type 2 diabetes … Read more
The SURMOUNT-1 study laid the scientific foundation for the use of tirzepatide in obesity. A detailed analysis of the game-changing results. Published in the New England Journal of Medicine in July 2022, the SURMOUNT-1 study is the pivotal clinical trial that led to the authorization of tirzepatide (Zepbound) for the treatment of obesity. With 2,539 participants … Read more
Survodutide, retatrutide, orforglipron: molecules that could surpass Mounjaro are already in advanced clinical trials. While tirzepatide (Mounjaro/Zepbound) has revolutionized obesity treatment with its dual GIP/GLP-1 action, pharmaceutical research doesn’t stop. Several new-generation molecules are under development, promising even more impressive results. An overview of treatments that could redefine obesity management in the coming years. Read more
Tirzepatide does more than just reduce appetite: it simultaneously acts on three vital organs to combat obesity and type 2 diabetes. Tirzepatide, the active ingredient in Mounjaro and Zepbound, is often presented as a simple injectable appetite suppressant. This reductive view ignores the complexity of its mechanism of action. In reality, this … Read more
From Mediator to Fen-Phen and rimonabant: the history of anti-obesity treatments and why GLP-1s represent a revolution.
A comprehensive overview of GLP-1 agonists available in France in 2026: Mounjaro, Ozempic, Wegovy, Trulicity. Comparison, reimbursement, and future molecules.
GIP receptors are the key differentiating factor for Mounjaro. Their role in adipose tissue, the brain, and bones explains the superiority of tirzepatide.